Showing posts with label Drug. Show all posts
Showing posts with label Drug. Show all posts
Wednesday, August 2, 2017
HIV Drug Side Effects in Kenya
Today's post is a video report from Kenya, where older HIV medications are still the first line of treatment because they are cheaper. Neuropathy isn't mentioned by name in the video but Zerit and the other so-called D-drugs are. These are well-known as being primary causes of neuropathy as a side effect for HIV people. The video highlights a dilemma in many poorer societies. Better a drug regime that controls the virus but has side effects, than no treatment at all. However, in the First World where those older drugs are much less used and actively discouraged, it's emerging that neuropathy can appear anyway; probably stemming from the virus itself and its attacks on the nervous system but that's not the point. For many thousands of people in poorer countries, they will have to endure the side effects until the most advanced drug regimes become affordable for all. These are simple political decisions by both governments who can subsidise and drug companies who can cut the prices. Unfortunately, the drug companies are still preoccupied with the bottom line and will generally only discount the older HAART medications - their side effects are the price that has to be paid.
Monday, June 19, 2017
Mirogabalin A New Drug For Neuropathy
Today's post from medivizor.com (see link below) looks at a new drug designed to treat neuropathic symptoms. It looks as though it may be a possible substitute for Lyrica (pregabalin) but with less side-effects and that has to be a good thing considering the bad press that pregabalin gets. As so often, the article is aimed at diabetics with neuropathy but if it's a possible substitute for pregabalin, then it will be prescribed for many people with neuropathy from other causes. The problem is, there has only been one small study on humans to date and whether the conclusions drawn are enough to convince you or not, there needs to be more research, especially on the effects on the various major forms and causes of neuropathy. Pregabalin, for instance, is issued to some neuropathy patients and is not recommended for others, depending on the cause of the nerve damage - clarity and evidence are essential.

Posted by Medivizor on Jul 10, 2015 in Diabetes mellitus
In a nutshell
This study examined whether mirogabalin is safe and effective in diabetics with peripheral neuropathy.
Some background
Chronic high blood glucose levels can lead to damage to blood vessels in patients with diabetes. This can result in various complications, such as eye disease, kidney disease and diabetic neuropathy. Diabetic neuropathy is a condition in which the nervous system becomes injured. Approximately 50% of diabetics who have neuropathy experience peripheral neuropathic pain (PNP – chronic pain in legs and arms). PNP can result in depression, anxiety and sleep disorders.
Pregabalin (Lyrica) is a drug currently used to treat PNP, however it is poorly tolerated. In addition, 50% of patients require pregabalin along with another drug in order to achieve pain relief. Mirogabalin is a similar drug to pregabalin, but is believed to have fewer side effects. Its use in treating PNP is currently being investigated.
Methods & findings
This study aimed to determine the safety and most effective dose of mirogabalin.
This study involved 452 diabetic patients divided into 7 groups. One group of patients received a placebo (a substance with no therapeutic effect). 5 groups received mirogabalin at different doses (5, 10, 15, 20 or 30 mg per day). One group received 300 mg pregabalin daily. Participants received the drug or placebo for 5 weeks.
Participants recorded their pain score at the start of the study and throughout the study. All participants had an average daily pain score greater than 4 (maximum score of 11). Mirogabalin had a clinically significant effect if it reduced the daily pain score by 1.
In comparison to the placebo group, participants receiving mirogabalin had a greater decrease in pain. This decrease was greater with a higher dose (pain score difference of -0.53 for 10 mg vs. -1.01 for 30 mg). This decrease was also greater than participants using pregabalin (pain score difference of -0.05 for pregabalin compared to placebo).
61% of participants experienced side effects. 9.4% experienced mild to moderate dizziness, while 6.1% experienced headaches.
The bottom line
This study concluded that 30 mg of mirogabalin reduces pain in diabetics with PNP and is well-tolerated.
The fine print
This study only assessed the effects of mirogabalin over 5 weeks. It is not known whether mirogabalin is safe or effective for long-term use. As some participants experienced side effects, this drug may not be suitable for all patients. The author received funding from Daiichi Sankyo, the company who developed the drug.
Published By :
Diabetes Care
Date :
Sep 17, 2014
Original Title :
Efficacy and Safety of Mirogabalin (DS-5565) for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Adaptive Proof-of-Concept Phase 2 Study.
https://medivizor.com/blog/SampleLibrary/diabetes-mellitus/mirogabalin-a-potential-new-drug-to-treat-pain-in-diabetics-with-peripheral-neuropathy/
Friday, May 12, 2017
Lpathomab A Future Drug For Neuropathic Pain
Today's post from cnbc.com (see link below) is a tually a press-release and therefore an advertisement for a new treatment for neuropathy which has been submitted to the FDA for approval. Normally, this blog doesn't advertise in any form but when a new drug seems to be promising and will engender interest among neuropathy patients, it has to be noted. The drug, Lpathomab, "is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain." This may mean little to the casual reader but is indicative of the depth of study now being put into neuropathic pain treatments. It is becoming clear that studies at molecular level are becoming more sophisticated and showing real promise of real solutions in the future. Whether Lpathomab turns out to be successful or not, is the question and it has to be said that the company are pretty much at the beginning of the process leading to a drug on the shelves. They need FDA approval to continue their development plans but although it may be difficult to pronounce, keep Lpathomab in the back of your mind as being a possibility for the future.
Monday, 2 Feb 2015 | 8:00 AM ETPR Newswire
SAN DIEGO, Feb. 2, 2015 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), a leader in the discovery and development of lipid-targeted therapeutics, announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete and the study has been approved by the trial sites' investigational review boards.
Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.
"We've made great progress in advancing Lpathomab towards the clinic and are eager to start our first-in-human study for our third antibody product candidate produced using our ImmuneY2TM drug discovery engine," said Dario Paggiarino, M.D., chief development officer of Lpath. "We believe our approach of targeting the ligand (LPA) with an antibody may have distinct mechanistic advantages over traditional small molecule approaches to address an area of significant unmet medical need."
About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN) is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, for neuropathic pain and an anti-leukotriene antibody, Altepan, which is being studied in models of inflammatory bowel disease, respiratory disease and inflammation. For more information, visit www.Lpath.com.
Forward-Looking Statements
Lpath cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Lpath's business, including, without limitation: Lpath may not be permitted by the FDA to proceed with the Phase 1 clinical trial of Lpathomab on a timely basis, without first being required to conduct additional studies, or at all; the final results of Lpath's preclinical studies and clinical trials may be different from Lpath's studies or interim data results and may not support further clinical development and/or the commercialization of its drug candidates; Lpath may not successfully complete its existing and any additional clinical trials for its drug candidates on a timely basis, or at all; Lpath may fail to obtain required governmental approvals for any of its drug candidates; Lpath may not be successful in maintaining its commercial relationship with Pfizer Inc. or any third party that may acquire the exclusive option Lpath granted to Pfizer for iSONEP; and Lpath may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the risk factors and uncertainties that may affect the realization of forward-looking statements is set forth in Lpath's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Such documents may be read free of charge on the SEC's website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which are effective only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Lpath undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
COMPANY CONTACT:
Gary Atkinson
Chief Financial Officer
Lpath, Inc.
858-926-3202
gatkinson@lpath.com
PUBLIC RELATIONS CONTACT:
Canale Communications
Rachel Hutman
619-849-5384
rachel@canalecomm.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lpath-submits-investigational-new-drug-application-for-lpathomab-for-neuropathic-pain-300028833.html
SOURCE Lpath, Inc.
http://www.cnbc.com/id/102388470#.
Saturday, April 29, 2017
DRUG USED TO TREAT GLAUCOMA ACTUALLY GROWS HUMAN HAIR
If you're balding and want your hair to grow back, then here is some good news. A new research report appearing online in The FASEB Journalshows how the FDA-approved glaucoma drug, bimatoprost, causes human hair to regrow. It's been commercially available as a way to lengthen eyelashes, but these data are the first to show that it can actually grow human hair from the scalp
"We hope this study will lead to the development of a new therapy for balding which should improve the quality of life for many people with hair loss," said Valerie Randall, a researcher involved in the work from the University of Bradford, Bradford, UK. "Further research should increase our understanding of how hair follicles work and thereby allow new therapeutic approaches for many hair growth disorders."
To make this discovery, Randall and colleagues conducted three sets of experiments. Two involved human cells and the other involved mice. The tests on human cells involved using hair follicles growing in organ culture as well as those take directly from the human scalp. In both of these experiments, the scientists found that bimatoprost led to hair growth. The third set of experiments involved applying bimatoprost to the skin of bald spots on mice. As was the case with human cells, the drug caused hair to regrow.
"This discovery could be the long-awaited follow up to Viagra that middle-aged men have been waiting for," said Gerald Weissmann, MD, editor-in-chief of The FASEB Journal. "Given that the drug is already approved for human use and its safety profile is generally understood, this looks like a promising discovery that has been right in front of our eyes the whole time. On to the front of our scalp!"
Subscribe to:
Posts (Atom)